Lamotrigine-loaded chitosan-sodium alginate polymeric nanoparticle system optimized by BoxBehnken Design demonstrated improved release control, enhanced pharmacokinetic parameters, and superior anticonvulsant activity in vivo, supporting their potential as a sustained-release system for epilepsy management.
Abstract
The clinical utility of lamotrigine in epilepsy is limited by poor aqueous
solubility, variable oral absorption, short half-life, and P-glycoprotein-mediated efflux at the
blood-brain barrier. This study aimed to develop an optimized chitosan-sodium alginate
polymeric nanoparticle system for Lamotrigine with desired physicochemical characteristics and
enhanced in vivo performance.
Nanoparticles were prepared by the emulsification-solvent evaporation method. A
Box-Behnken design guided the optimization of polymer concentration and sonication time.
Formulations were characterized for particle size, polydispersity index, zeta potential, drug
content, entrapment efficiency, and in vitro release behavior. Release kinetics were evaluated
using standard mathematical models. Pharmacodynamic studies (MES, PTZ, and GABA
estimation) were performed in mice, whereas pharmacokinetic studies were carried out in rats
The optimized batch LP7 exhibited a particle size of 168.7 nm, entrapment efficiency of
85.91%, and smooth spherical morphology. LP7 released 89.11% of drug within 24 hours via
non-Fickian diffusion. In vivo pharmacokinetic studies showed significantly higher Cmax, AUC,
and half-life with enhanced brain drug levels compared to pure drug. MES and PTZ models
demonstrated reduced seizure duration and prominent anticonvulsant protection. GABA levels
were significantly elevated in treated groups.
The nanoparticle system achieved controlled drug release, improved stability,
and enhanced brain transport. Pharmacokinetic and pharmacodynamic data confirmed sustained
systemic exposure and superior seizure control at reduced doses.
Lamotrigine-loaded chitosan-sodium alginate nanoparticles optimized by BoxBehnken Design demonstrated improved release control, enhanced pharmacokinetic parameters,
and superior anticonvulsant activity in vivo, supporting their potential as a sustained-release
system for epilepsy management.
The developed nanoliposomal system offers significant clinical advantages including potential for enhanced tumor targeting, reduced dosing frequency, and minimized systemic toxicity, pending in vivo validation, and improved therapeutic outcomes.
Mayur R. Nikam, D. Sonawane, A. Pawar· BioNanoScience· 0 citations
The developed chitosan-coated Eudragit® S100 nanoparticle system represents a promising platform for sustained, colon-targeted oral delivery of HSP and other poorly bioavailable bioactive compounds.
PLGA-based nanoparticles successfully enhanced the bioavailability of voglibose and provided sustained release, highlighting their potential as a novel delivery system for anti-diabetic therapy.
Parimita Kalita, R. Jesudasan, Kalyani Pathak et al.· Drug Delivery Letters· 0 citations
INTRODUCTION/OBJECTIVE
Ebastine, a second-generation H1 antihistamine, exhibits poor aqueous solubility and consequently low oral bioavailability, limiting its clinical therapeutic efficacy. Novasome is an advanced vesicular nanocarrier system that offers a promising approach to enhance the solubility and dissolution b...
Salam ShantaTaher, Hussein J. Alhazza, H. Alkufi et al.· Recent Advances in Drug Deli...· 0 citations
The optimized BDNL3 formulations showed a sustained release profile and a 2.15-fold increase in bioavailability, which may provide a potential approach to overcome its poor oral absorption and improve therapeutic outcomes.
R. Rajmane, A. Joshi, Dhanashri Desai· Journal of Pharmaceutical In...· 0 citations